Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$0.00$0.00no prior Q1 2020 on file Net Income-$18.22M-$18.22MN/M vs Q1 2020 EPS Diluted-$0.28-$0.28N/M vs Q1 2020 Operating Income-$18,209,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$19,980,000N/M ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end